Literature DB >> 30081064

(F)Utility of the physical crossmatch for living donor evaluations in the age of the virtual crossmatch.

Harold C Sullivan1, Christina L Dean2, Robert S Liwski3, Shilpee Biswas2, Abigail L Goodman2, Scott Krummey2, Howard M Gebel2, Robert A Bray2.   

Abstract

Flow cytometric crossmatches (FCXM) are routinely performed to support living-donor renal transplantation. While long a laboratory mainstay, a physical crossmatch is costly, time consuming, and frequently poses interpretative conundrums with both false-positive and false- negative results. Given the increased utilization of the virtual crossmatch (vXM) in the deceased donor setting, our aim was to assess its utility in living donor evaluations. We reviewed 100 living donor FCXMs and retrospectively performed a vXM for each pair. Seventy-five (75) cases were concordant, (i.e., FCXM-/vXM- or FCXM+/vXM+) while 25 cases were discordant; Five were vXM+/FCXM- and 20 were FCXM+/vXM-. Since donor-specific antibodies (DSA) were not detected in the 20 FCXM+/vXM- cases, these were interpreted as false-positive, i.e., due to non-HLA antibodies. Importantly, none of these patients, when transplanted across a positive FCXM, experienced early antibody mediated rejection or subsequently developed HLA DSA. These data reveal that, for the vast majority of living donor evaluations, a vXM is an acceptable vetting procedure.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Crossmatch; FCXM; HLA; SAB; Virtual crossmatch; vXM

Mesh:

Year:  2018        PMID: 30081064     DOI: 10.1016/j.humimm.2018.08.001

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  5 in total

1.  Identification of a recurrent pattern of false-positivity by Luminex HLA MHC class I single antigen bead testing.

Authors:  Christina L Dean; Scott M Krummey; Howard M Gebel; Robert A Bray; Harold C Sullivan
Journal:  Hum Immunol       Date:  2020-01-06       Impact factor: 2.850

2.  Virtual Crossmatching in Kidney Transplantation, Shiraz Experience in Development of a Web-Based Program.

Authors:  N Jamshidian Tehrani; B Geramizadeh; S A Malekhosseini; S Nikeghbalian; A Bahador; S Gholami; G A Raees Jalali; J Roozbeh; M H Anbardar; N Soleimani; N Rasaei; S Mohammadzadeh
Journal:  Int J Organ Transplant Med       Date:  2021

Review 3.  BSHI/BTS guidance on crossmatching before deceased donor kidney transplantation.

Authors:  S Peacock; D Briggs; M Barnardo; R Battle; P Brookes; C Callaghan; B Clark; C Collins; S Day; N Diaz Burlinson; P Dunn; R Fernando; S Fuggle; A Harmer; D Kallon; D Keegan; T Key; E Lawson; S Lloyd; J Martin; J McCaughan; D Middleton; F Partheniou; A Poles; T Rees; D Sage; E Santos-Nunez; O Shaw; M Willicombe; J Worthington
Journal:  Int J Immunogenet       Date:  2021-09-23       Impact factor: 2.385

4.  Trends and impact on cold ischemia time and clinical outcomes using virtual crossmatch for deceased donor kidney transplantation in the United States.

Authors:  Chethan M Puttarajappa; Dana Jorgensen; Jonathan G Yabes; Kwonho Jeong; Adriana Zeevi; John Lunz; Amit D Tevar; Michele Molinari; Sumit Mohan; Sundaram Hariharan
Journal:  Kidney Int       Date:  2021-04-30       Impact factor: 18.998

5.  Utilizing nanopore sequencing technology for the rapid and comprehensive characterization of eleven HLA loci; addressing the need for deceased donor expedited HLA typing.

Authors:  Timothy L Mosbruger; Amalia Dinou; Jamie L Duke; Deborah Ferriola; Hilary Mehler; Ioanna Pagkrati; Georgios Damianos; Eric Mbunwe; Mahdi Sarmady; Ioannis Lyratzakis; Sarah A Tishkoff; Anh Dinh; Dimitri S Monos
Journal:  Hum Immunol       Date:  2020-06-25       Impact factor: 2.850

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.